Segments - Viral Clearance Market by Applications (Cellular & Gene Therapy Products, Blood & Blood Products, Vaccines & Therapeutics, Tissue & Tissue Products, and Stem Cell Products), Methods (Viral Inactivation Method, Viral Detection Method, and Viral Removal Method), End-users (Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Academic Research Institutes, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The global viral clearance market size was valued at USD 595.32 Million in 2022 and is expected to reach USD 3486.31 Million by 2031, expanding at a CAGR of 21.7% during the forecast period, 2023-2031. The growth of the market is attributed to the rising government funding for the pharmaceutical and biotechnology industries.
Viruses are types of organisms that are responsible for various infectious diseases that can reproduce rapidly inside the living cells of human beings. Viruses generally infect all types of life forms including animals and plants. Viruses have the ability to multiply on their own and can infect animal or human cell.
They also have the ability to infect bacterial cells by damaging the cell and bringing out their multiplication and growth in the host cell. The infected cell produces viral particles rather than their regular products. The analysis of the capability to produce a risk-free product and ensure the safety of the product for human use is a vital aspect of viral clearance method.
Several technical calculation are deployed to gauge the level of the products safety by controlling the presence or infection by virus during the manufacturing of the product. To achieve this agenda, there is a requirement to eventually conduct viral clearance and implementation of viral safety assessment in the course of product evolution.
Viral infections affect bioreactor contamination, raw materials, downstream processing, and cell culture processes. This is expected to help in forming the demand for viral safety practice and the implementation of the virus clearance process.
The report on the global viral clearance market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Viral Clearance Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast The development of a Rapid Viral Clearance Predictive In-Silico Tool represents a significant advancement in the field of viral safety. This innovative tool utilizes computational models to predict the efficacy of viral clearance processes, offering a faster and more cost-effective alternative to traditional methods. By simulating various scenarios and assessing potential risks, the in-silico tool enables researchers and manufacturers to optimize their viral clearance strategies. This not only accelerates the development timeline but also enhances the reliability of the viral clearance process, ensuring that biopharmaceutical products are free from viral contaminants. As the industry continues to evolve, such predictive tools are expected to play a pivotal role in maintaining high safety standards. |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Applications (Cellular & Gene Therapy Products, Blood & Blood Products, Vaccines & Therapeutics, Tissue & Tissue Products, and Stem Cell Products), Methods (Viral Inactivation Method, Viral Detection Method, and Viral Removal Method), End-users (Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Academic Research Institutes, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Lonza Group; Charles River Laboratories International, Inc.; Sigma-Aldrich Corporation; Merck KGaA; Avance Biosciences Inc.; Clean Cells; BSL Bioservice Scientific Laboratories GmbH; SGS S.A.; Texcell, Inc.; and WuXi PharmaTech Inc. |
Based on applications, the global viral clearance market is divided into cellular & gene therapy products, blood & blood products, vaccines & therapeutics, tissue & tissue products, and stem cell products.
The vaccines & therapeutics segment is expected to account for a key share of the market during the projected period due to advance wide development of new vaccines and implementation of advanced therapeutic procedures introduced in the market. However, the cellular & gene therapy products segment is anticipated to expand at a rapid pace during the forecast period owing to various awareness campaigns by market players and healthcare authorities.
On the basis of methods, the market is segmented into viral inactivation method, viral detection method, and viral removal method.
The viral inactivation method segment is projected to expand at a considerable CAGR during the forecast period owing to various R&D activities to enhance the procedure. On the other hand, the viral removal method segment is anticipated to expand at an impressive growth rate during the forecast period due to technology advancement in the field.
In terms of end-users, the global viral clearance market is classified into contract research organizations, pharmaceutical & biotechnology companies, academic research institutes, and other.
The contract research organizations segment is expected to exhibit robust growth of the market in the coming years owing to increasing investments by key market players towards several research organizations to enhance their products.
Meanwhile, the academic research institutes segment is anticipated to expand at a healthy growth rate during the forecast period due to supportive government policies towards academic institutions.
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America accounted for a key share of the market in 2019 and is anticipated to constitute a key market share during the targeted period due to rising awareness and increasing investments by healthcare authorities towards viral clinical research in the region.
The market of Asia Pacific, however, is anticipated to expand at a rapid pace during the forecast period owing to increasing healthcare expenditure and developing healthcare infrastructure in the region.
The global viral clearance market has been segmented on the basis of
Key players competing in the global viral clearance market are Lonza Group; Charles River Laboratories International, Inc.; Sigma-Aldrich Corporation; Merck KGaA; Avance Biosciences Inc.; Clean Cells; BSL Bioservice Scientific Laboratories GmbH; SGS S.A.; Texcell, Inc.; and Wuxi PharmaTech Inc.
The main market players are continuously looking for several market development activities and opportunities such as mergers and acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market positions.
The market is segmented by applications (such as vaccines, gene therapy, blood products), methods (inactivation, detection, removal), end-users (CROs, pharma/biotech companies, academic institutes), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).
Trends include the development of innovative viral clearance techniques, increased R&D activities for novel drugs, and a strong product pipeline in the pharmaceutical industry.
Key players include Lonza Group, Charles River Laboratories International, Inc., Sigma-Aldrich Corporation, Merck KGaA, Avance Biosciences Inc., Clean Cells, BSL Bioservice Scientific Laboratories GmbH, SGS S.A., Texcell, Inc., and WuXi PharmaTech Inc.
A high degree of market consolidation is a major restraint, potentially limiting competition and innovation in the viral clearance market.
Major end-users are contract research organizations, pharmaceutical & biotechnology companies, academic research institutes, and others.
The primary methods for viral clearance include viral inactivation, viral detection, and viral removal, with viral inactivation and removal methods seeing significant advancements and growth.
Viral clearance is mainly applied in cellular & gene therapy products, blood & blood products, vaccines & therapeutics, tissue & tissue products, and stem cell products.
North America holds a significant share of the viral clearance market due to high awareness and investments in viral clinical research, while Asia Pacific is expected to grow rapidly due to increasing healthcare expenditure and infrastructure development.
Key growth drivers include rising government funding for pharmaceutical and biotechnology industries, increasing demand for product safety, development of innovative viral clearance techniques, and strict government regulations on quality control.
The global viral clearance market was valued at USD 595.32 million in 2022 and is projected to reach USD 3,486.31 million by 2031, expanding at a CAGR of 21.7% from 2023 to 2031.